Loading...
Sera Prognostics Q1 2025 Earnings Report
Sera Prognostics reported its first quarter 2025 financial results, showing an increase in revenue and a slight increase in net loss compared to the same period in the previous year.
Key Takeaways
Sera Prognostics reported first quarter 2025 revenue of $38,000, up from nil in the prior year. The company's net loss for the quarter was $8.2 million, a slight increase from $8.1 million in the prior-year quarter. Total operating expenses were $9.3 million, compared to $9.1 million in the first quarter of 2024.
First quarter 2025 revenue was $38,000, compared to nil for the same period of 2024.
Net loss for the quarter was $8.2 million compared to $8.1 million for the prior-year quarter.
Total operating expenses were $9.3 million, compared with $9.1 million for the first quarter of 2024.
Research and development expenses decreased by approximately 9% due to lower clinical study costs, while selling, general and administrative expenses increased to drive future growth.
Sera Prognostics
Sera Prognostics
Forward Guidance
Sera Prognostics is focused on leveraging the PRIME study results to engage with payors and plan administrators, pursuing Medicaid opportunities, and cultivating interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm.
Positive Outlook
- Elevating engagement with payors and plan administrators following positive PRIME study results.
- Pursuing Medicaid opportunity, which represents approximately half of the market opportunity for Sera's PreTRM® Test.
- Discussions with several Medicaid plans across three states for PreTRM test implementation pilots.
- Strong presence expected at upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting to cultivate interest in evidence generation.
- Anticipating positive impact of PreTRM on healthcare cost savings and patient outcomes, furthering adoption of the test.
Challenges Ahead
- It will take some time for the Medicaid provider engagement to evolve and for adoption of the test to increase.
- The company's ability to introduce new products and potential competition are ongoing risks.
- Dependence on a concentrated number of material customers.
- Potential for changes in FDA regulation of laboratory-developed tests.
- Risks related to intellectual property rights and market position.